CDC researchers analyzed clinical data from 187 hospitals in nine states between Jan. 17 and Sept. 5.
Two doses of an mRNA vaccine were 77 percent effective at preventing COVID-19 hospitalizations among immunocompromised adults, compared to 90 percent for immunocompetent adults. This difference was consistent across vaccine types, patient age groups and the timing of hospitalizations relative to the delta variant’s dominance in each state.
“Immunocompromised persons benefit from COVID-19 mRNA vaccination but are less protected from severe COVID-19 outcomes than are immunocompetent persons,” the CDC said.
The finding builds on past research suggesting immunocompromised people may not develop high levels of antibodies after vaccination. Per CDC recommendations, these individuals should receive three doses of an mRNA vaccine, along with a booster.
The CDC estimates about 3 percent of adults in the U.S. are immunocompromised.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
